- Home
- ELUT vs PRPO Comparison
ELUT vs PRPO Comparison
Compare ELUT & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELUT | PRPO |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 40.1M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ELUT | PRPO |
|---|---|---|
| Price | $0.94 | $24.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 86.4K | 16.1K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | $12,293,000.00 | ★ $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.50 | $12.46 |
| 52 Week High | $2.60 | $33.63 |
Technical Indicators
Market Signals| Indicator | ELUT | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 59.95 |
| Support Level | $0.86 | $22.05 |
| Resistance Level | $0.99 | $25.27 |
| Average True Range (ATR) | 0.06 | 1.44 |
| MACD | -0.00 | 0.46 |
| Stochastic Oscillator | 13.75 | 85.12 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.